收藏切换
Comparison of clinical efficacy between pentoxifylline and Xuesaitong in the treatment of acute cerebral infarction
收藏切换
Ke HU, Guoxiang TAN, Qiwu XU*
World Clinical Drug | 2023, 44(9) : 953 - 958
Less
收藏切换
World Clinical Drug | 2023, 44(9): 953-958
• Article •
Comparison of clinical efficacy between pentoxifylline and Xuesaitong in the treatment of acute cerebral infarction
Full
Ke HU, Guoxiang TAN, Qiwu XU*
Affiliations
  • Department of Neurology, Tongling Municipal Hospital, Tongling 244100, Anhui Province, China
Published: 2023-09-10 doi: 10.13683/j.wph.2023.09.010
Outline
收藏切换
Objective

To compare the clinical efficacy of pentoxifylline and Xuesaitong in the treatment of acute cerebral infarction (ACI).

Methods

A total of 160 patients with ACI hospitalized in department of neurology, Tongling municipal hospital from July 2020 to July 2022 were selected as the research objects. They were divided into observation group and control group, with 80 cases in each group. The observation group was given pentoxifylline on the basis of conventional treatment, and the control group was given Xuesaitong on the basis of conventional treatment. National Institute of Health stroke scale (NIHSS) and mini-mental state examination (MMSE) were used to evaluate the degree of neurological impairment and cognitive function. The clinical efficacy, changes of plasma fibrinogen (FIB) and hypersensitivity C-reaction protein (hs-CRP) levels before and after treatment were compared between the two groups, and the adverse reactions were observed.

Results

The effective rate of observation group was higher than that of control group (86.25% vs 71.25%, P<0.05). After treatment, the MMSE scores of both groups increased compared to before treatment (P<0.05), while the NIHSS score and FIB level decreased compared to before treatment (P<0.05), and the improvements of the observation group were better than those of the control group (P<0.05). The incidence of progressive cerebral infarction in the observation group was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion

Pentoxifylline has better clinical efficacy than Xuesaitong in the treatment of ACI, which can effectively improve neurological deficits symptoms and cognitive function, and reduce the levels of plasma FIB and hs-CRP, and it is rather safe.

pentoxifylline  /  Xuesaitong  /  acute cerebral infarction  /  fibrinogen  /  high sensitivity C-reactive protein
胡克, 檀国祥, 许啟伍. 己酮可可碱和血塞通对急性脑梗死的临床疗效比较. 世界临床药物, 2023 , 44 (9) : 953 -958 . DOI: 10.13683/j.wph.2023.09.010
Ke HU, Guoxiang TAN, Qiwu XU. Comparison of clinical efficacy between pentoxifylline and Xuesaitong in the treatment of acute cerebral infarction[J]. World Clinical Drug, 2023 , 44 (9) : 953 -958 . DOI: 10.13683/j.wph.2023.09.010
Year 2023 volume 44 Issue 9
13
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.09.010
  • Receive Date:2023-01-29
  • Online Date:2026-11-18
  • Published:2023-09-10
Article Data
Affiliations
History
  • Received:2023-01-29
Funding
Affiliations
    Department of Neurology, Tongling Municipal Hospital, Tongling 244100, Anhui Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.09.010
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT